case 2: long-term braf/mek data in melanoma
Published 4 years ago • 314 plays • Length 6:44Download video MP4
Download video MP3
Similar videos
-
7:31
case 2: braf-mutated metastatic melanoma
-
8:40
melanoma: braf/mek targeted therapy
-
8:13
case 2: frontline decisions in stage iv braf-mutant melanoma
-
1:28
jeffrey weber, md, phd: the impact of braf/mek inhibitors in melanoma
-
20:35
hitting the mark with targeted therapy: braf, nras, ckit, etc...sullivan
-
1:06
jason luke, md: the impact of braf/mek inhibitors in melanoma
-
6:22
braf and mek in melanoma
-
9:49
melanoma: nuances of braf/mek combinations in the front line
-
8:47
braf/mek inhibitors in metastatic melanoma
-
22:44
braf targeted therapy - melanoma education symposium, peter boasberg md
-
1:09
rationale for mek/braf combinations in melanoma
-
0:53
dabrafenib plus trametinib demonstrates benefit in braf-mutant melanoma
-
1:12
exploring treatment options for patients with advanced melanoma
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
1:03
five-year os data for dabrafenib/trametinib combo in melanoma
-
7:23
melanoma: braf/mek-inhibitors as adjuvant therapy
-
4:07
understanding resistance to combined braf and mek inhibiton in melanoma and the significance of cdk4
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
6:05
duration of dual braf-mek inhibition